First patient in Vivolux’s study completes treatment at third dose level of VLX1570 drug candidate

Vivolux said vast amounts of defective proteins formed in tumor cells disrupt the functioning of proteasome.

The new mechanism of action by VLX1570 has been indicated to inhibit tumor growth and increase survival in several preclinical models of multiple myeloma, including those that show resistance to other cancer treatments.

Vivolux is undertaking the clinical study in partnership with the Memorial Sloan-Kettering Cancer Center in New York and the Dana-Farber Cancer Institute at Harvard Medical School in Boston.

The first phase is designed to identify the safety and maximum tolerated dose of VLX1570 in patients with multiple myeloma who are no longer benefiting from conventional cancer treatment.

Phase two includes the investigation of the clinical efficacy of VLX1570, which acts on the proteasome via a new mechanism of action.

Vivolux CEO and founder Hans Rosén said: We have a strong scientific basis for VLX1570 and the expectations are high that this new approach to treating cancer will make a significant difference for cancer patients.

"We look forward to establishing the therapeutic dose and to evaluating VLX1570 on multiple myeloma patients."

VLX600 is Vivolux’s first drug candidate to be evaluated at the clinical phase. The study is being undertaken in collaboration with the Mayo Clinic Cancer Centers in the US.